Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting
04:44am, Thursday, 06'th Nov 2025
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line.
2 Dirt Cheap Stocks to Buy With $1,000 Right Now
04:10am, Thursday, 06'th Nov 2025
Turnaround stocks often face a lot of negativity from investors until their turnaround efforts start bearing fruit. United Parcel Service is working to streamline its operations so it can become a mor
Metsera Issues Statement in Response to Litigation Ruling
07:17pm, Wednesday, 05'th Nov 2025
NEW YORK , Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Compa
Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman
06:02pm, Wednesday, 05'th Nov 2025
Evan David Seigerman, BMO, joins 'Fast Money' to talk bidding wars in the pharma space, Novo Nordisk dropping on earnings, and more.
Pfizer Responds to Delaware Chancery Court Ruling
05:08pm, Wednesday, 05'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order
Pfizer preparing to raise its bid for Metsera, WSJ reports
05:02pm, Wednesday, 05'th Nov 2025
Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.
Delaware judge says she will not block Metsera from ending Pfizer deal
04:20pm, Wednesday, 05'th Nov 2025
A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $
Pfizer says it removed some conditions from its Metsera bid
02:19pm, Wednesday, 05'th Nov 2025
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Dela
Pfizer: Market Still Pricing It At Crisis Valuations
11:30am, Wednesday, 05'th Nov 2025
Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer mul
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
10:07am, Wednesday, 05'th Nov 2025
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera
05:42am, Wednesday, 05'th Nov 2025
Management lowers full-year guidance, warns about competition, launches bid for Metsera.
3 Magnificent Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 8.5% -- to Buy With Confidence in November
03:06am, Wednesday, 05'th Nov 2025
Dividend stocks have more than doubled the average annual return of non-payers over the last 51 years. Phenomenal deals can be found among ultra-high-yield dividend stocks -- those with yields four or
Traders Buy Large Volume of Pfizer Call Options (NYSE:PFE)
01:18am, Wednesday, 05'th Nov 2025
Pfizer Inc. (NYSE: PFE - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock traders bought 190,383 call options on the company. This is an increase of 16% compared
Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic Milestones
04:14pm, Tuesday, 04'th Nov 2025
Revenue: $16.7 billion for Q3 2025, a 7% operational decrease year-over-year.Adjusted Diluted EPS: $0.87, ahead of expectations.Reported Diluted EPS: $0.62 for
